Traws Pharma, Inc. (NASDAQ:TRAW – Get Free Report) shares fell 0.1% during mid-day trading on Friday . The company traded as low as $8.47 and last traded at $8.66. 180,366 shares traded hands during trading, a decline of 22% from the average session volume of 231,983 shares. The stock had previously closed at $8.67.
Traws Pharma Trading Down 0.1 %
The firm’s 50-day moving average is $6.06. The company has a market cap of $26.21 million, a PE ratio of -0.06 and a beta of 1.13.
Traws Pharma Company Profile
Traws Pharma, Inc, a clinical stage biopharmaceutical company, focuses on developing small molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID19 that are designed to address treatment resistance, such as TRX01 (travatrelvir), a Mpro/3CL inhibitor in development for the treatment of COVID19; and TRX100 (viroxavir), an endonuclease inhibitor in development for the treatment of pandemic influenza.
Featured Stories
- Five stocks we like better than Traws Pharma
- What is a buyback in stocks? A comprehensive guide for investors
- Cold Front, Hot Stocks: Diesel Prices Propel Energy Leaders
- How to invest in marijuana stocks in 7 steps
- Sustainable and Successful: 3 Climate ETFs Beating the Market
- What Are Treasury Bonds?
- Quantum Opportunity: Skywater Technology’s Long-Term Potential
Receive News & Ratings for Traws Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Traws Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
